Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M...

|By:, SA News Editor

Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M upfront plus milestone payouts of up to $880M to develop and market experimental cancer drug vintafolide, which is being evaluated in a Phase 3 clinical trial for ovarian cancer and a Phase 2 trial for non-small cell lung cancer. (PR)